Aadi Bioscience, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Whitehawk Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $22.2 million and a strategic shift towards antibody-drug conjugates (ADCs).
Whitehawk Therapeutics, Inc. reported a strategic pivot to its preclinical antibody-drug conjugate pipeline following the divestiture of its FYARRO business, significantly improving its cash position and reducing its accumulated deficit.
Whitehawk Therapeutics completed the divestiture of its FYARRO business and secured significant financing to advance its new preclinical antibody-drug conjugate pipeline.
10-Q: Whitehawk Therapeutics Reports Q1 2025 Results, Fueled by FYARRO Divestiture and New ADC Focus
Whitehawk Therapeutics reports a profitable Q1 2025 driven by the sale of its FYARRO business, shifting focus to preclinical ADC therapies.
Aadi Bioscience reports Q3 results, halts a key clinical trial, and initiates a strategic review to maximize shareholder value.
Aadi Bioscience's Q2 2024 results show a slight decrease in revenue compared to the same period last year, alongside ongoing clinical development and strategic adjustments.
Aadi Bioscience reported a net loss of $18.3 million for the first quarter of 2024, with product sales of $5.4 million, and provided updates on its clinical trials.